SCHEMBL3750452

SCHEMBL3750452

NC(=O)C1N=Cc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.43
LMNA P02545 2/20 0.34
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 2/20 0.32
MAPK1 P28482 1/20 0.32
SCN4A P35499 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN9A Q15858 1/20 0.32
CYP2C19 P33261 2/20 0.31
HSD17B10 Q99714 2/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.31
PARP1 P09874 1/20 0.31
MAPT P10636 1/20 0.31
RECQL P46063 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5323003 0.86 ATM (0.39) ATMLMNATSHRHSD17B10POLB
SCHEMBL27775308 0.69 ATM (0.36) ATMLMNAALDH1A1GAATSHR
SCHEMBL19376306 0.69 ATM (0.36) ATMLMNAALDH1A1GAATSHR
SCHEMBL28445883 0.69 MAOA (0.33) GAAMEN1KMT2AHTR2A
SCHEMBL6045293 0.69 HTR2A (0.35) GAAMEN1KMT2AHTR2A
SCHEMBL9298612 0.68 POLB (0.34) ALDH1A1POLBHDAC4
Hydrochloric Acid SCHEMBL7724483 0.67 KDM1A (0.36) HTR2A
SCHEMBL943810 0.66 EGFR (0.32) LMNAGAATSHRMAPK1SCN4A
Citenamide SCHEMBL636661 0.65 ATM (0.57) ATMLMNAALDH1A1GAATSHR
Citenamide SCHEMBL29446009 0.65 ATM (0.57) ATMLMNAALDH1A1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638661-A1 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS Astrazeneca AB (SE) 2020-04-22 EP claimed
WO-2018229155-A1 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS ASTRAZENECA AB (SE) 2018-12-20 WO claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101528690-A Isoindoline derivatives for the treatment of arrhythmias ASTRAZENECA AB (SE) 2009-09-09 CN claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 US disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 US disclosed
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof AMGEN INC. (US) 2020-07-28 US disclosed
US-20200223830-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF CYTOKINETICS, INC. 2020-07-16 US disclosed
US-20200223829-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2020-07-16 US disclosed
US-20190077793-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2019-03-14 US disclosed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
WO-2009145718-A1 ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS ASTRAZENECA AB (SE) 2009-12-03 WO disclosed
CN-101528690-A Isoindoline derivatives for the treatment of arrhythmias ASTRAZENECA AB (SE) 2009-09-09 CN disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-20200223830-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-20200223829-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-20190077793-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof TNNI3, TNNT2, TNNC1 ATM 3596/4885LMNA 52/4885ALDH1A1 4627/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 ATM 4357/4885LMNA 228/4885ALDH1A1 315/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 ATM 3953/4885LMNA 42/4885ALDH1A1 3628/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 ATM 2001/4885LMNA 461/4885ALDH1A1 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.